View in EDS HTML Full Text PDF Full Text

Icotinib, an EGFR tyrosine kinase inhibitor, as adjuvant therapy for patients with stage IIA-IIIA EGFR-mutant non-small-cell lung adenocarcinoma: a multicenter, open-label, single-arm, phase II study (ICAPE).

Saved in:
Bibliographic Details
Title: Icotinib, an EGFR tyrosine kinase inhibitor, as adjuvant therapy for patients with stage IIA-IIIA EGFR-mutant non-small-cell lung adenocarcinoma: a multicenter, open-label, single-arm, phase II study (ICAPE).
Authors: Qian K; Department of Thoracic Surgery, Xuanwu Hospital, Capital Medical University, No. 45, Changchun Street, Xicheng District, 100053, Beijing, China., Chen QR; Department of Thoracic Surgery, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China., He M; Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China., Wang ZT; Department of Thoracic Surgery, Beijing Chest Hospital, Capital Medical University, Beijing, China., Liu Y; Second Department of Thoracic Surgery, Handan Central Hospital, East District, Handan, Hebei, China., Liang HG; Department of Thoracic Surgery, The First Hospital of Qinhuangdao, Qinhuangdao, Hebei, China., Su ZY; Department of Thoracic Surgery, Affiliated Hospital of Chifeng University, Chifeng, Neimenggu, China., Cui YS; Department of Thoracic Surgery, Peking Union Medical College Hospital, Beijing, China., Liu LJ; Department of Thoracic Surgery, Hebei Province People's Hospital, Shijiazhuang, Hebei, China., Zhang Y; Department of Thoracic Surgery, Xuanwu Hospital, Capital Medical University, No. 45, Changchun Street, Xicheng District, 100053, Beijing, China. xuanwuhosp@163.com.
Source: Investigational new drugs [Invest New Drugs] 2023 Feb; Vol. 41 (1), pp. 44-52. Date of Electronic Publication: 2022 Nov 10.
Publication Type: Clinical Trial, Phase II; Multicenter Study; Journal Article
Journal Info: Publisher: Springer Country of Publication: United States NLM ID: 8309330 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-0646 (Electronic) Linking ISSN: 01676997 NLM ISO Abbreviation: Invest New Drugs Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 36355317
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Icotinib, an EGFR tyrosine kinase inhibitor, as adjuvant therapy for patients with stage IIA-IIIA EGFR-mutant non-small-cell lung adenocarcinoma: a multicenter, open-label, single-arm, phase II study (ICAPE).
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Qian+K%22">Qian K</searchLink>; Department of Thoracic Surgery, Xuanwu Hospital, Capital Medical University, No. 45, Changchun Street, Xicheng District, 100053, Beijing, China.<br /><searchLink fieldCode="AU" term="%22Chen+QR%22">Chen QR</searchLink>; Department of Thoracic Surgery, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.<br /><searchLink fieldCode="AU" term="%22He+M%22">He M</searchLink>; Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.<br /><searchLink fieldCode="AU" term="%22Wang+ZT%22">Wang ZT</searchLink>; Department of Thoracic Surgery, Beijing Chest Hospital, Capital Medical University, Beijing, China.<br /><searchLink fieldCode="AU" term="%22Liu+Y%22">Liu Y</searchLink>; Second Department of Thoracic Surgery, Handan Central Hospital, East District, Handan, Hebei, China.<br /><searchLink fieldCode="AU" term="%22Liang+HG%22">Liang HG</searchLink>; Department of Thoracic Surgery, The First Hospital of Qinhuangdao, Qinhuangdao, Hebei, China.<br /><searchLink fieldCode="AU" term="%22Su+ZY%22">Su ZY</searchLink>; Department of Thoracic Surgery, Affiliated Hospital of Chifeng University, Chifeng, Neimenggu, China.<br /><searchLink fieldCode="AU" term="%22Cui+YS%22">Cui YS</searchLink>; Department of Thoracic Surgery, Peking Union Medical College Hospital, Beijing, China.<br /><searchLink fieldCode="AU" term="%22Liu+LJ%22">Liu LJ</searchLink>; Department of Thoracic Surgery, Hebei Province People's Hospital, Shijiazhuang, Hebei, China.<br /><searchLink fieldCode="AU" term="%22Zhang+Y%22">Zhang Y</searchLink>; Department of Thoracic Surgery, Xuanwu Hospital, Capital Medical University, No. 45, Changchun Street, Xicheng District, 100053, Beijing, China. xuanwuhosp@163.com.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228309330%22">Investigational new drugs</searchLink> [Invest New Drugs] 2023 Feb; Vol. 41 (1), pp. 44-52. <i>Date of Electronic Publication: </i>2022 Nov 10.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase II; Multicenter Study; Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer%22">Springer </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>8309330 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1573-0646 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2201676997%22">01676997 </searchLink><i>NLM ISO Abbreviation: </i>Invest New Drugs <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=36355317
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s10637-022-01316-5
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 44
    Titles:
      – TitleFull: Icotinib, an EGFR tyrosine kinase inhibitor, as adjuvant therapy for patients with stage IIA-IIIA EGFR-mutant non-small-cell lung adenocarcinoma: a multicenter, open-label, single-arm, phase II study (ICAPE).
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Qian K
      – PersonEntity:
          Name:
            NameFull: Chen QR
      – PersonEntity:
          Name:
            NameFull: He M
      – PersonEntity:
          Name:
            NameFull: Wang ZT
      – PersonEntity:
          Name:
            NameFull: Liu Y
      – PersonEntity:
          Name:
            NameFull: Liang HG
      – PersonEntity:
          Name:
            NameFull: Su ZY
      – PersonEntity:
          Name:
            NameFull: Cui YS
      – PersonEntity:
          Name:
            NameFull: Liu LJ
      – PersonEntity:
          Name:
            NameFull: Zhang Y
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 02
              Text: 2023 Feb
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-electronic
              Value: 1573-0646
          Numbering:
            – Type: volume
              Value: 41
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Investigational new drugs
              Type: main
ResultId 1